Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Speciality: Hematology
Description:
Welcome to our podcast on the latest in hematology. In recent months, advances in diagnostics and treatment have transformed patient care. Innovative molecular techniques now allow for earlier detection of blood disorders, while targeted therapies are improving outcomes in conditions like leukemia and lymphoma. Researchers are also exploring gene editing and immunotherapy, offering new hope for previously untreatable cases. Additionally, updated guidelines emphasize the importance of personalized medicine, ensuring therapies are tailored to each individual’s genetic profile. Staying informed about these developments is essential for clinicians and patients alike, as the field of hematology continues to evolve rapidly. Thank you for joining us for this comprehensive update.
See More Webinars @ Hidoc Webinars
1.
A US health panel advises starting mammograms at age 40 rather than 50.
2.
Infection Burden High With Myeloma T-Cell Therapies
3.
Study opens up possibility of bespoke prostate cancer treatment
4.
There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.
5.
How Much of a Cancer Drug Is Too Much?
1.
Ear Emergency: Understanding the Causes and Treatment for Auricular Hematoma
2.
TAR-200 in Bladder Cancer: Precision Drug Delivery Driving Oncology Advances
3.
Interpreting Iron Studies: What Your Blood Results Really Mean
4.
Immune Ecosystem Remodeling Within Solid Tumor Niches
5.
The Benefits and Risks of Thrombolytics: A Comprehensive Guide
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part XV
2.
Efficient Management of First line ALK-rearranged NSCLC - Part VIII
3.
From Guidelines to Practice: Hematology
4.
First Line Combination Therapy- The Overall Survival Data in NSCLC Patients
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge